RBC Capital analyst Brian Abrahams downgraded Gilead to Sector Perform from Outperform with an unchanged price target of $87. The analyst expects continued good operational execution, but believes it will "take time to gain more definitive visibility on the next sets of meaningful potential drivers." Abrahams would remain holders of Gilead given its "low-risk" profile and good long-term prospects and would look to add to positions on any dips. But with the stock up 40% from the late-September lows and approaching his fair value of $87, he believes the stock is "more likely to settle in at this new range in the coming year."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead downgraded to Sector Perform from Outperform at RBC Capital
- Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5
- Biotech Alert: Searches spiking for these stocks today
- Opco reveals three biotech stocks that will outperform in 2023
- Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M